

**Minutes of the HSE Directorate meeting
Tuesday 19th January, 2016**

Directorate Members Present: S. Mulvany (A/Chairman), P. Healy, J. Hennessy, L. Woods, S. O’Keeffe, A. O’Connor and P. Crowley

Members of Leadership Team present: Á. Carroll, D. McCallion, P. Lynch, P. Connors, M. Flynn, J. Coffey, J. Carolan, R. Mannion and R Corbridge.

Apologies: T. O’Brien
In attendance: J. Ryan, J. O’Sullivan and D. Purcell (Secretary)
Joined the Meeting: B. Hyland

Time & Location: Boardroom, Dr. Steevens’ Hospital, Dublin 8

Item	Discussion / Comments	Action
1	Draft Divisional Operational Plans	
	<p>National Directors reported on the preparation of the Operational Plans 2016 by Division. The draft plans circulated prior to the meeting had also been shared with the relevant line divisions in the DoH and their feedback is awaited.</p> <p><u>Actions agreed:</u></p> <ul style="list-style-type: none"> • All National Directors to review the current draft Operational Plans and provide any feedback directly to the relevant National Directors. • Divisional Operational Plans to be finalised and circulated to the Leadership Team by Wednesday 27th January 2016. • Special Leadership Team meeting to be arranged for Thursday 28th January 2016. • Hospital Group and CHO plans to be completed and signed off by the relevant National Directors by Friday 19th February 2016. • Arrangements for the publication of Divisional Operational Plans and the Hospital Group and CHO plans to be discussed further at the special Leadership Team meeting on the 28th January 2016. 	<p>National Directors</p> <p>National Directors</p> <p>Secretary</p> <p>Relevant National Directors</p> <p>Agenda Item 28/01/16</p>
2	Social Care Capital Proposals in relation to HIQA Compliance in Public Residential Care Facilities	
	<p>2.1 Capital Plan 2016-2021 Public Residential Care Centres Older People P. Healy presented the Capital Plan 2016-2021 Public Residential Care Centres Older People to deliver full compliance with the minimum physical/environmental standards set by HIQA for registration purposes. The Programme sets out the centres to be refurbished, centres to be replaced, new centres to be opened between 2016 and 2021 and those centres to be replaced by Public Private Partnership or alternative funding mechanism by the end of 2021.</p> <p>He also outlined the additional funding requirement of €37m in respect of five centres to enable the HSE to submit a complete plan to HIQA for full compliance across all centres and centres where additional capacity could be provided.</p> <p>J. Carolan reported that HBS Estates had been working closely with the Social Care Division on the proposals for €498m and confirmed that they were consistent with the Capital Plan 2016-2021.</p> <p><u>Action agreed:</u> It was agreed that the €37m funding requirement needs to be additional, new Capital money and not taken from other Capital money already provided.</p> <p>2.2 Social Care Disabilities Capital Plan 2016 P. Healy presented the Social Care Disabilities Capital Plan for 2016 which provides for €20m capital funding which is being prioritised to support the accelerated implementation of the recommendations of the report on congregated settings, “A Time to Move on from Congregated Settings”, and the projects for submission to the Department of the Environment as part of the Capital</p>	

	<p>Assistance Scheme (CAS-DECLG).</p> <p><u>Action agreed:</u></p> <ul style="list-style-type: none"> • It was agreed that the proposals would be included in the Capital Plan for 2016. J. Carolan to ensure alignment with the Capital Plan 2016. • All revenue costs associated with acquisition of properties must be met as part of existing levels of service as no additional funding is being provided. <p>The great work done by M. Fitzgerald, Social Care, Services for Older People and J. Browner, HBS Estates in putting together the Social Care Older People and Disabilities Capital Funding Plans was acknowledged.</p>	<p>J. Carolan</p>
<p>3</p>	<p>Approvals in Accordance with the Reserved Functions of the Directorate</p>	
	<p>Health Business Services - Contract Approval Requests</p> <p>3.1 Direct Negotiations with GlaxoSmithKline Ltd. for the Supply of Meningococcal B Vaccine and 3.2 Direct Negotiations with GlaxoSmithKline Ltd. for the Supply of HIB/Meningococcal C Vaccine (MenC) Combined Vaccine (taken together)</p> <p>J. Carolan spoke to the briefing paper circulated prior to the meeting providing clarifications arising from the decisions (<i>Directorate Decision Numbers 12.01(05)2016 and 12.01(06)2016</i>) by the Directorate on the 12th January 2016 to approve the awarding of the contracts for the supply of Meningococcal B Vaccine and HIB/Meningococcal C (MenC) Combined Vaccine by a negotiated procedure under Article 31(1)(b) of the EU Procurement Directives, subject to conditions.</p> <p>J. Carolan informed the meeting that it would not be possible to attach conditions to the contract and therefore the contracts would have to be reconsidered by the Directorate. She confirmed that the contracts would be for seven years for the volume specified in the CARs and that the HSE contract price is comparable to the UK price.</p> <p>The Directorate expressed concern in relation to the risk of entering into a contract for the supply of the vaccines without yet having agreement with GPs regarding its administration. S. O’Keeffe spoke to the letter tabled at the meeting from the Chief Medical Officer, DoH in relation to the implementation of changes to the Primary Childhood Immunisation Schedule 2016 and reported on recent engagement with the DoH in this regard.</p> <p>Given that the extension of the Primary Childhood Immunisation Schedule is a Ministerial priority and there was a request from the DoH to introduce the vaccine in Q4, 2016, approval to award the contracts for the supply of Meningococcal B Vaccine and HIB/Meningococcal C (MenC) Combined Vaccine by a negotiated procedure under Article 31(1)(b) of the EU Procurement Directives was proposed by S. O’Keeffe, seconded by P. Crowley and agreed. This was subject to a letter issuing to the DoH setting out the aforementioned risks and requesting by return that the DoH are happy for the HSE to proceed on this basis.</p> <p><i>Directorate Decision No.19.01(09)2016 (Men B) & Directorate Decision No.19.01(09)2016 (HIB/Men C)</i></p> <p><u>Action agreed:</u></p> <p>S. O’Keeffe to reply to the CMO highlighting the concerns of the Directorate in relation to the risk discussed regarding the administration of the vaccines and to receive response from DoH to same.</p>	<p>S. O’Keeffe</p>

The meeting concluded at 3.25pm

Signed:

Date:

Stephen Mulvany
A/Chairman